Signaling Lymphocytic Activation Molecule Family, Member 7 (SLAMF7) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Rabbit Polyclonal against the SLAMF7 protein.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Signaling Lymphocytic Activation Molecule Family, Member 7 (SLAMF7) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by antigen affinity column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, WB, IHC |
| Buffer | Prior to lyophilization: 1% BSA and 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | BC027867 |
| Alias | CD2 subset 1,19A,CS1,CD319,CRACC,CD2-like receptor-activating cytotoxic cells,Membrane protein FOAP-12 |
| Background | Antibody anti-SLAMF7 |
| Status | RUO |
| Note | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. - |
Descripción
SLAMF7 (SLAM Family Member 7), also known as CS1 (CD2 subset 1) or CRACC (CD319), is a cell surface glycoprotein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family within the immunoglobulin superfamily. SLAMF7 is primarily expressed on the surface of immune cells, especially on natural killer (NK) cells, plasma cells, and certain T-cell subsets, as well as dendritic cells and monocytes. This receptor plays a key role in immune cell activation, adhesion, and signal transduction, significantly influencing immune responses. SLAMF7 is particularly relevant in the context of immune surveillance and tumor cell recognition, as it acts as a co-stimulatory molecule for NK cells, enhancing their cytotoxic function against abnormal cells. In the tumor microenvironment, SLAMF7 can either promote anti-tumor immunity or, in some cases, contribute to immune evasion mechanisms that facilitate cancer cell survival. Its expression in multiple myeloma, where it is typically highly expressed, has made it a target for immunotherapy. The development of monoclonal antibodies against SLAMF7, like elotuzumab, has underscored its significance in cancer therapy.
Related Products
Human SLAMF7 (SLAM family member 7)ELISA Kit
Ver Producto
anti- SLAMF7 antibody
Self-ligand receptor of the signaling lymphocytic activation molecule(SLAM) family. SLAM receptors triggered by homo-or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway(PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K(PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells(By similarity). May play a role in lymphocyte adhesion(PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines(PubMed:23695528). Isoform 3 does not mediate any NK cell activation.
Ver Producto